New Progression-Free Survival Data From Peregrine’s Bavituximab in Phase II Refractory Breast Cancer Trial to Be …

New Progression-Free Survival Data From Peregrine’s Bavituximab in Phase II Refractory Breast Cancer Trial to Be …
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced new median progression-free survival (PFS) data of 7.4 months from a Phase II trial evaluating bavituximab in combination with docetaxel in refractory patients with advanced breast cancer. Best …

Read more on SYS-CON Media

More Meth Drug Addiction Info:

• Penny Stocks Alert
• Physicians use MRI to Detect Early Breast Cancer
• Obama has all responsibility, no control over BP disaster – London …
• Preclinical Development Of Monoclonal Antibodies And Related …
• Two Doctors Misread 2 Mammograms And Did Not Detect Woman's Cancer …
• Watch Survival of the Dead (2010) Movie Free Online | Watch Movie …
• Breast Cancer Survival Rate | GEEK!
• A Movie a Day, Day 13: Survival of the Dead | The House Next Door
• Example 7.38: Kaplan-Meier survival estimates | (Articles about R)
• lung cancer survivor stories | Print World